【摘要】 目的:观察多西他赛为主方案治疗晚期乳腺癌的疗效及不良反应。方法:共有46例晚期乳腺癌患者接受治疗。初次化疗者及既往未使用过蒽环类者24例,接受多西他赛加吡柔吡星方案化疗,吡柔吡星40mg·(m2)-1,静脉冲入,第1天,多西他赛75mg·(m2)-1,静脉滴注1小时,第2天;既往使用过蒽环类治疗失败者22例,接受多西他赛加顺铂方案化疗,多西他赛75mg·(m2)-1,静脉滴注1小时,第1天,顺铂25～30mg·(m2)-1,静脉滴注,第2～5天。至少化疗2个周期以后评价疗效,按WHO标准进行评价。结果:46例患者CR3例,PR21例,NC13例,PD9例,有效率52.2%(24/46),毒性反应主要为骨髓抑制和脱发。结论:多西他赛为主化疗方案治疗晚期乳腺癌疗效确切,毒性反应能耐受。更多还原

【Abstract】 OBJECTIVE:To observe the efficacy and toxicity of docetaxel-based combination chemotherapy for advanced breast cancer. METHODS:A total of 46 patients with advanced breast cancer were enrolled,of whom,24 who had never been treated with anthracene nucleus were initially treated with pirarubicin 40 mg·(m2)-1 by intravenous injection on day 1 followed by 1 hour’s intravenous drop infusion of Docetaxel 75 mg·(m2)-1 on day 2; another 22 cases who had been treated with anthracene nucleus but failed to show response were given Docetaxel 75 mg·(m2)-1 by drip infusion for 1 hour on day 1 followed by drip infusion of cisplatin 25～30 mg·(m2)-1 from day 2 to day 5. After treatment for at least two courses,the clinical response of patients was evaluated based on criteria recommended by WHO. RESULTS:Of the 46 patients following treatment with docetaxel-based combined chemotherapy,the numbers of patients showing complete response (CR),partial response (PR),NC,progressive disease (PD) were 3,21,13,and 9,respectively,and the overall response rate was 52.2% (24/46). The major toxicities were myelosuppression and alopecia. CONCLUSION:The docetaxel-based combined chemotherapy is effective and tolerable in patients with advanced breast cancer.更多还原